Gyre Pharmaceuticals Receives IND Approval From Center For Drug Evaluation Of China's NMPA To Evaluate F230 For The Treatment Of Pulmonary Arterial Hypertension

Gyre Therapeutics, Inc. - Common Stock +6.42%

Gyre Therapeutics, Inc. - Common Stock

GYRE

13.42

+6.42%

Gyre Therapeutics ("Gyre") (NASDAQ:GYRE), a clinical-stage, self-sustainable biotechnology company developing anti-fibrotic therapeutics for a variety of chronic organ diseases, today announced that the Center for Drug Evaluation ("CDE") of China's National Medical Products Administration ("NMPA") has approved Gyre Pharmaceuticals' (Gyre's indirectly controlled subsidiary) Investigational New Drug ("IND") application for F230 tablets, a selective endothelin receptor antagonist, for the treatment of pulmonary arterial hypertension ("PAH"). F230 was originally licensed from Eisai through Gyre's indirect majority stockholder, GNI Group Ltd.

Every question you ask will be answered
Scan the QR code to contact us
whatsapp
Also you can contact us via